Feb 7th 2023 - Mar 21st 2023
$AVXL thanks yet again Bill.
Worth the risk with patience and not investing lif... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.$AVXL thanks yet again Bill.
Worth the risk with patience and not investing lifestyle or bill money.
But, after cognition tests the trial passed all endpoints!
THEN they said it hadnt passed any trials, well gee whiz now met BOTH secondary Endpoints. Newsflash.
Blarcamesine passed every endpoints. .
Key is we passed all endpoints with statically significant results!
Hahah .. passed easily!
Passed it all no problem!
After TLR, Anavex will be the owner of a first-in-class, patented, medically-proven, high-demand asset that merely needs to pass through the technicality of government approval to qualify it for mass marketing.
No reviews available.
